Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 6 June 2018, 10am to 5.30pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:
1. Dr Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Professor John Cairns Present for all notes
4. Mr David Chandler Present for all notes
5. Mr Mark Chapman Present for all notes
6. Mr Diar Fattah Present for all notes
7. Ms Susan Faulds Present for all notes
8. Mr Richard Hoddes Present for all notes
9. Dr Mona Johnson Present for all notes
10.Dr Sanjay Kinra Present for all notes
11. Mr Chris O'Regan Present for all notes
12. Professor Stephen Palmer Present for notes 18 to 42
13. Professor Sarah Wild Present for all notes
14. Dr Stuart Williams Present for all notes

In attendance:

Melinda Goodall Associate Director, National Institute for Health and Care Excellence Present for all notes

Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes

Sandra Aleknavice Administrator, National Institute for Health and Care Excellence Present for all notes

Mary Hughes Technical Analyst, National Institute for Health and Care Excellence Present for notes 1 to 17

Ahmed Elsada Technical Adviser, National Institute for Health and Clinical Excellence Present for notes 1 to 17
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Walker</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>18 to 30</td>
</tr>
<tr>
<td>Rebecca Albrow</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>18 to 30</td>
</tr>
<tr>
<td>Sharlene Ting</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>31 to 42</td>
</tr>
<tr>
<td>Jasdeep Hayre</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>31 to 42</td>
</tr>
<tr>
<td>Professor Joanne Lord</td>
<td>Director, Southampton Health Technology Assessment Centre</td>
<td>1 to 15</td>
</tr>
<tr>
<td>Dr Jo Picot</td>
<td>Senior Research Fellow, Southampton Health Technology Assessment Centre</td>
<td>1 to 15</td>
</tr>
<tr>
<td>Professor Peter Clark</td>
<td>Chair of NHS England Chemotherapy Clinical Reference Group and National Clinical Lead for CDF</td>
<td>1 to 17</td>
</tr>
<tr>
<td>Professor Graham Jackson</td>
<td>Professor of Clinical Haematology, Newcastle Upon Tyne Hospitals Trust, clinical expert nominated by Janssen</td>
<td>5 to 13</td>
</tr>
<tr>
<td>Dr Matthew Streetly</td>
<td>Consultant Haematologist, Guys and St. Thomas’ NHS Foundation Trust, clinical expert nominated by the UKMF</td>
<td>5 to 13</td>
</tr>
<tr>
<td>Mrs Carmen Lester</td>
<td>Patient expert nominated by Myeloma UK</td>
<td>5 to 13</td>
</tr>
<tr>
<td>Ms Shelagh McKinlay</td>
<td>Head of Patient Advocacy, Myeloma UK, patient expert nominated by Myeloma UK</td>
<td>5 to 13</td>
</tr>
<tr>
<td>Dr Xavier Armoiry</td>
<td>Senior Research Fellow, Warwick Evidence</td>
<td>18 to 28</td>
</tr>
<tr>
<td>Mr Peter Auguste</td>
<td>Research Fellow, Warwick Evidence</td>
<td>18 to 28</td>
</tr>
<tr>
<td>Dr Peter Brex</td>
<td>Consultant Neurologist, King’s College Hospital</td>
<td>18 to 26</td>
</tr>
</tbody>
</table>
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974], ocrelizumab for treating
primary progressive multiple sclerosis [ID938] and padeliporfin for treating localised prostate cancer [ID866].

2. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Adam Brooke, Ross Dent, Marcela Haasova, Chloe Kastoryano and Edgar Masanga.

3. Apologies were received from Dr Mark Glover, Dr Nicholas Latimer, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton and Mr Nigel Westwood.

Any other Business

4. The Committee were given an update on the progress of other appraisals previously seen by the Committee and an update on personnel changes within the NICE Technology Appraisals team.

Appraisal of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974]

Part 1 – Open session

5. The Chair welcomed the invited experts: Professor Joanne Lord, Dr Jo Picot, Professor Peter Clark, Professor Graham Jackson, Dr Matthew Streetly, Mrs Carmen Lester and Ms Shelagh McKinlay to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Janssen to the meeting.

7. The Chair asked all Committee members to declare any relevant interests.

7.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr David Chandler, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Mr Chris O'Regan, Professor Sarah Wild and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].

7.2. Professor Stephen Palmer declared a non-personal specific financial interest before the meeting as he has received consultancy fees from Amgen for general technical advice.

9.2.1 It was agreed that this declaration would prevent Professor Palmer from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab in
combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Professor Joanne Lord, Dr Jo Picot, Professor Peter Clark, Mrs Carmen Lester and Dr Matthew Streetly declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].

9.2. Professor Graham Jackson declared a personal specific financial interest as he has received speaker fees from Janssen and from other pharmaceutical companies involved in this area.

9.2.1. It was agreed that this declaration would not prevent Professor Jackson from participating in this section of the meeting.

9.3. Ms Shelagh McKinlay declared a non-personal non-specific financial interest as Myeloma UK receives 12% of its funding from pharmaceutical companies.

9.3.1. It was agreed that this declaration would not prevent Ms McKinlay from participating in this section of the meeting.

10. The Chair introduced the lead team, Ms Susan Faulds and Mr Christopher O'Regan who gave presentations on the clinical effectiveness and cost effectiveness of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
16. The Committee continued to discuss the clinical and cost effectiveness of daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974].

16.1. The committee decision was based on consensus.

17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

**Appraisal of ocrelizumab for treating primary progressive multiple sclerosis [ID938]**

**Part 1 – Open session**

18. The Chair welcomed the invited experts: Dr Xavier Armoiry, Mr Peter Auguste, Dr Peter Brex, Dr Alistair Coles, Mr Craig Milverton, Mrs Yvonne Pettigrew and Mr Malcolm Qualie to the meeting and they introduced themselves to the Committee.

19. The Chair welcomed company representatives from Roche to the meeting.

20. The Chair asked all Committee members to declare any relevant interests.

20.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr David Chandler, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Mr Chris O'Regan, Professor Stephen Palmer, Professor Sarah Wild and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ocrelizumab for treating primary progressive multiple sclerosis [ID938].

21. The Chair asked all NICE Staff to declare any relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ocrelizumab for treating primary progressive multiple sclerosis [ID938].

22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

22.1. Dr Xavier Armoiry, Mr Peter Auguste, Mr Craig Milverton, Mrs Yvonne Pettigrew and Mr Malcolm Qualie declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ocrelizumab for treating primary progressive multiple sclerosis [ID938].
22.2. Dr Peter Brex declared a personal specific financial interest as he has undertaken consultancy work for Roche and other pharmaceutical companies.
   22.2.1. It was agreed that this declaration would not prevent Dr Brex from participating in this section of the meeting.

22.3. Dr Alistair Coles declared a personal non specific financial interest as he has received payments from Genzyme.
   22.3.1. It was agreed that this declaration would not prevent Dr Coles from participating in this section of the meeting.

23. The Chair introduced the lead team, Mr David Chandler, Mr Richard Hoddes and Dr Sanjeev Patel who gave presentations on the clinical effectiveness and cost effectiveness of ocrelizumab for treating primary progressive multiple sclerosis [ID938].

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

26. The Chair then thanked the clinical and patient experts for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. Discussion on confidential information continued. This information was supplied by the company.

28. The Chair then thanked the Evidence Review Group and company representatives and Mr Malcolm Qualie for their attendance, participation and contribution to the appraisal and they left the meeting.

29. The Committee continued to discuss the clinical and cost effectiveness of ocrelizumab for treating primary progressive multiple sclerosis [ID938].
   29.1. The committee decision was based on consensus.

30. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of padeliporfin for treating localised prostate cancer [ID866]

Part 1 – Open session

31. The Chair welcomed the invited experts: Mr Dwayne Boyers, Miss Maria Dimitrova, Mr Dolapo Ayansina, Professor Mark Emberton and Miss Caroline Moore to the meeting and they introduced themselves to the Committee.

32. The Chair welcomed company representatives from Steba Biotech to the meeting.
33. The Chair asked all Committee members to declare any relevant interests.

33.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr David Chandler, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Mr Chris O'Regan, Professor Stephen Palmer, Professor Sarah Wild and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of padeliporfin for treating localised prostate cancer [ID866].

34. The Chair asked all NICE Staff to declare any relevant interests.

34.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of padeliporfin for treating localised prostate cancer [ID866].

35. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

35.1. Mr Dwayne Boyers, Miss Maria Dimitrova and Mr Dolapo Ayansina declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of padeliporfin for treating localised prostate cancer [ID866].

35.2. Professor Mark Emberton declared a personal specific financial interest as he has received meeting expenses from Steba Biotech and participated in advisory boards for Steba Biotech.

35.2.1. It was agreed that this declaration would not prevent Professor Emberton from participating in this section of the meeting.

35.3. Miss Caroline Moore declared a personal specific financial interest as he has received meeting expenses from Steba Biotech and participated in advisory boards for Steba Biotech.

35.3.1. It was agreed that this declaration would not prevent Miss Moore from participating in this section of the meeting.

36. The Chair introduced the lead team, Professor John Cairns and Professor Sarah Wild who gave presentations on the clinical effectiveness and cost effectiveness of padeliporfin for treating localised prostate cancer [ID866].

37. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

38. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to
Meetings) Act 1960)” and all public attendees left the meeting.

39. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

40. Discussion on confidential information continued. This information was supplied by the company.

41. The Committee continued to discuss the clinical and cost effectiveness of padeliporfin for treating localised prostate cancer [ID866].

41.1. The committee decision was based on consensus.

42. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

**Date, time and venue of the next meeting**

Tuesday 10 July 2018 at 10 Spring Gardens, London SW1A 2BU.